Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
66.0% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Lyell Immunopharma and Neuphoria Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Profitability
This table compares Lyell Immunopharma and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
Risk and Volatility
Lyell Immunopharma has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Valuation and Earnings
This table compares Lyell Immunopharma and Neuphoria Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 5,334.88 | -$274.45 million | ($12.83) | -0.68 |
| Neuphoria Therapeutics | $1.17 million | 15.43 | -$13.45 million | ($6.22) | -0.54 |
Neuphoria Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Neuphoria Therapeutics beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
